Pfizer (PFE)

Total return at 5 years: 5.5%/year = -0.9% appreciation + 6.4% dividend. The target price ($28) is ex-dividend; the $9 in dividends collected over 5 years are added separately.

By both methods, the value today (DCF $61 · Multiples $30) exceeds the market price ($29).

Today — fairly valued: at $29 trades ~4.3% below its value discounted to today (~$30); the discount is positive but does not reach the margin of safety we require (≥38%).

At 5 years — En valor: the target price ($28) plus dividends yield between the 4% floor and the 10% average return — a reasonable return, though without the margin of a great investment.

The bridge: the return at 5 years exceeds the risk-free rate (4.5%) — but the discount does not reach the required margin of safety (≥38%). To require a 15% annual return, it would need to be bought at ~$20.

Educational / informational. Does not constitute investment advice.

The inverse approach: instead of projecting growth to obtain the value, the market price ($29) is taken as given and it solves for what annual owner-earnings growth would need to hold for 5 years for the present value —at the method's rate (4.5%, no-growth terminal)— to equal that price. It is the disconfirmation test: the expectations the price already pays for, contrasted against the method's projection.

The market discounts less growth (-10.4%/year) than we project (2.5%/year) → if the base case holds, there is margin: perception is more pessimistic than the estimated reality.

That growth implies ~$9.3 bn of owner earnings in year 5 (vs ~$18.2 bn of our base case). It recalculates if the DCF assumptions are edited.

Year-by-year projection of the selected scenario. From each year, two versions of the flow are derived: growth FCF (operating flow − total capex, the cash surplus) and maintenance FCF (the owner earnings: what the business yields if it only sustains its capacity). The flow is returned almost in full (dividend + buyback) or redeployed into the operation, so that EV stays roughly flat and multiples compress because the metric grows, not because of cash accumulation. The valuation is done on NOPAT (EV/NOPAT). In edit mode, revenue, margins, capex, and exit multiples can be adjusted.

Year 0 is the TTM as of Jun-28-2026 ($63.7bn of revenue), which includes a second half of 2025 inflated by the seasonal concentration of Comirnaty in the fourth quarter. The company's guidance for calendar year 2026 ($60.5-62.5bn of revenue, midpoint $61.5bn) sits below the TTM level because COVID-19 products normalize toward an endemic/seasonal pattern (guidance of ~$4,000 million for 2026, against ~$6,700 million billed in 2025) while the rest of the portfolio grows at an ex-COVID pace of ~+6% operational. That is why the year-1 path anchors on guidance and falls versus the TTM —a valley, not a monotonic deceleration (rebound exception §5 R3)— and recovers growth from year 2 supported by Vyndaqel, Padcev, Lorbrena, oncology biosimilars and the post-2028 pipeline (Metsera, oncology ADC), moderated by the 2026-2030 patent cliff on Xeljanz, Prevnar 13, Adcetris, Eliquis and Ibrance. The operating margin expands gradually from the cost-savings programs (~$5.7bn of realignment + ~$1.5bn of manufacturing optimization + Seagen/Metsera synergies), from ~21.7% in the TTM toward ~23.4% in year 5 of the base case. The tax rate uses the adjusted effective rate the company publishes in its non-GAAP reconciliation (12.7% in 2025), because the GAAP effective rate (-3.5%) is a year-specific artifact from non-deductible impairments and discrete credits. Capex is treated as 100% maintenance (maintPct=1.0) because it runs below depreciation and amortization across the horizon, with no growth component to separate. Cash is not accumulated (accumulateCash=false, reinvestsExcess=true): the declared capital allocation framework prioritizes the dividend and balance-sheet deleveraging over cash accumulation or buybacks, which remain paused (zero in 2025 and year-to-date 2026). The base case's exit multiple (15x EV/NOPAT) sits near the floor of the pharmaceutical archetype's band [14x-22x] because return on capital (~8.9%) is below the 10% bar —weighed down by Seagen and Metsera goodwill— and the moat is in an erosion phase, not widening.

Today's elevated multiple is the price of growth: if the business grows, the entry point cheapens on its own going forward (the metric grows while EV stays roughly flat). The exit multiple at 3 years is higher than the terminal at 5 years —at 3 years there is more growth still ahead—, so the value curve shows whether value creation is concentrated in the early or the later years. The required return is applied to the base scenario.

They are valued separately, with their own rationale, and are not incorporated into the base or the verdict (they are excess return). When assigning them value — in Editmode —, the total with optionalities updates live, without moving the base.

The verdict, the base CAGR, and the margin of safety are always calculated on the base; optionalities do not alter them (with optionalities at $0 they do not move).

Each card fixes a required annual return and answers: if the business is worth $28 in 5 years, what is the maximum that can be paid today to obtain that return? Since it now trades at $29, the margin of safety is how much cheaper the market is than that maximum. The three thresholds: 4% covers inflation (the floor), 10% is the long-term average return, and 15% is the level of a great investment.

With a target price of $28 in 5 years plus $9 of dividends collected (the dividend adds to the return, not to the price) and a required return of 4.5% annually, the maximum to pay today is $30. Against the current market price ($29), the margin of safety is 4.3% (trades below the maximum → there is margin) and the total return at that price would be 5.5% annually.

• Chosen metric. EV/NOPAT on normalized owner earnings, consistent with the pharmaceutical archetype and the need to expense real maintenance capex.
• Exit multiple. ~15x EV/NOPAT in the base case, near the floor of the archetype's [14x-22x] band due to ROIC below the bar and a moat in erosion.
• Dividend yield. Today's dividend yield is 5.9%, with 349 consecutive quarterly payments and a capital framework that prioritizes sustaining it.
• Year-1 sensitivity. The path's year 1 starts below the TTM because the 2026 guidance anticipates a material decline in COVID-19 products.
• Cross-check against comparables. The implied terminal multiple is consistent with mature pharmaceutical peers with low-to-mid growth and at-risk patents.
• Earnings yield of the multiple. 1/15x ≈ 6.7% terminal earnings yield, consistent with a mature, not high-growth, business.

Each margin over sales, year by year: historical (solid line) → projection (dotted).

• ✕ ROIC exceeds the cost of capital (~10%)
• ✓ CFROIC backs up the ROIC (133%, cash vs. accruals)
• ✕ Healthy balance sheet (low corporate debt)
• ✓ Durable competitive moat (multiple advantages)

• Cash generation. TTM operating cash flow of $13.4bn comfortably covers maintenance capex (~$2.4bn) and the dividend.
• ROIC vs. the 10% bar. ~8.9% on invested capital of $140bn, below the bar — the typical pattern of a serial acquirer with accumulated goodwill.
• Reinvestment runway. The post-2028 pipeline (oncology ADC, Metsera) offers a reinvestment runway, but does not yet numerically offset the loss of exclusivity of products in the line.
• Earnings quality. TTM GAAP net income ($4.3bn) is depressed by non-recurring intangible impairments; 2025 adjusted income was $18.4bn.
• Cash conversion. TTM free cash flow (operating cash flow minus capex, ~$11bn) exceeds TTM GAAP net income, a signal that the gap is accounting-driven, not cash-driven.
• Stock-based compensation and dilution. Stock-based compensation is only ~1.5% of revenue and ~8.6% of FCF, with no material trap to correct in the metric.
• Working capital. No float superpower: receivables, inventory and payables move with the business cycle, without funding the operation.

Annual levels from the official filing (10-K); the % over each bar is the year-over-year (YoY) growth vs the prior year.

The four drivers show the business breakdown: the Biopharma reportable segment (98% of revenue), the gap between total revenue and ex-COVID-19 revenue (which reveals real underlying growth of +6% operational in 2025 against the reported -2% headline), the R&D spend that sustains the pipeline, and the declared dividend per share that anchors total return. Volume operating KPIs (prescriptions, units) are not reported on a consolidated basis by Pfizer beyond the individual per-product detail in the 10-K, so these financial drivers are the best available proxy without inventing a data point the filing does not report.

The % are the annual (year-over-year) growth: each year —historical and projected— vs the prior one; the TTM (trailing 12m) vs the TTM of a year ago, to avoid overlapping windows. The historicals are exact figures from the official filings; the projected years come from the year-by-year model (the intermediate years without their own series are interpolated between the anchors). The projected columns (+1y…+5y) are 12-month windows counted from the TTM close (28-jun-2026): the projection starts from the most recently reported data, not the fiscal year. The projected base is realistic and unbiased — the risk discount is applied at the end, via the required return. The rationale for each metric is in the (i).

• Ex-COVID-19 growth. +6% operational in 2025, driven by Vyndaqel (+16%), Padcev (+22%) and Lorbrena (+40%).
• 2026 guidance. Revenue guided at $60.5-62.5bn, with the $500 million upward adjustment to the midpoint offset by a $1,000 million reduction in COVID-19 product guidance.
• R&D pipeline. R&D spend of ~$10.4bn annually sustains a late-stage pipeline in oncology, hemophilia and weight management (Metsera).
• TAM and penetration. The global biopharmaceutical market keeps expanding due to population aging, but Pfizer competes for share against rivals with their own development pipelines.
• Risk of cliff reacceleration. Patent and exclusivity expirations in 2026-2030 are expected to 'accelerate significantly,' with Xeljanz, Prevnar 13 and Adcetris expiring in the U.S. in 2026.
• M&A as a growth lever. Metsera (Nov-2025) and Seagen (Dec-2023) add new lines, but dilute consolidated ROIC while they mature.

• Demand recurrence. Chronic medications (Eliquis, Vyndaqel, Ibrance) generate sustained repeat purchase due to the nature of the condition treated.
• Differentiated product vs. commodity. Patent-protected portfolio with twelve brands over $1 billion each; does not compete on price during the exclusivity window.
• Pricing power. The TrumpRx agreement and the IRA's Maximum Fair Price limit the ability to raise prices in the U.S. in the highest-margin tranche of the portfolio.
• Operating leverage. The cost realignment programs (~$5.7bn) and the Seagen and Metsera synergies (~$1.6bn) generate additional leverage without depending on revenue growth.
• Recession behavior. Demand for prescription drugs is largely inelastic to the economic cycle; Pfizer's risk is regulatory and patent-related, not cyclical.
• Revenue diversification. Twelve products account for 65% of 2025 revenue; none exceeds 13% (Eliquis), but the group is exposed to the same 2026-2030 expiration schedule.

Not all debt is equal: only the structural needs refinancing; the rest is operational (self-liquidating).

Structural debt is what is exposed to the contraction phase of the cycle; operational debt (leases, matched funding) self-liquidates with the business.

• !Leverage (net debt / EBITDA)Net debt / EBITDA 2.5x
• !Interest coverage (EBIT / interest)6.7x
• –Liquidity (current ratio)no data
• ✓Cash quality (CFROIC vs ROIC)CFROIC backs 133% of ROIC
• ✕Value creation (ROIC − 10% bar)-1pp
• ✓Malinvestment test (capex vs incremental ROIC)Capex/D&A 0.4x — no over-investment
• !Float / working capitalConsumes cash $0.2 bn (positive WC)
• ✓Dilution (SBC % of revenue + shares)SBC 1.5% of revenue

A traffic-light interpreted by the method (not generic): float (negative WC) adds up, capex is judged by incremental ROIC (malinvestment test), and a lender is not subjected to corporate solvency. The (i) shows the derivation of each number.

• Leverage. Gross debt of $63.1bn vs. cash and equivalents of $8.3bn; the company states its intention to keep deleveraging.
• Credit rating. A2 (Moody's) / A (S&P), stable investment grade.
• Interest coverage. Normalized operating income (~$14.2bn in FY2025) comfortably covers gross interest expense (~$2.7bn).
• Short-term liquidity. High-quality commercial paper, available revolving credit facilities and a P-1/A-1 short-term rating.
• Pending contractual obligations. Final payment of $2,600 million on the TCJA repatriation liability, due April 15, 2026.

Who owns the shares — the alignment and whether there is a controlling shareholder.

• CEO tenure. Albert Bourla has led the company since January 2019, with continuity in the capital allocation strategy.
• Capital allocation. The three declared pillars prioritize dividend and deleveraging; buybacks remain paused — zero in 2025 and year-to-date 2026.
• M&A track record. Seagen (~$43,000 million, Dec-2023) and Metsera (Nov-2025) are large bets whose return on capital has not yet been validated in the consolidated numbers.
• Alignment / skin in the game. No internal ownership detail verified in this pass — pending from the DEF 14A proxy.

• Missing buyers: market coverage is focused on the 2026-2030 patent cliff over twelve products that account for 65% of revenue, pushing growth investors out of the stock.
• Motivated sellers: TTM GAAP net income ($4.3bn) looks depressed against 2025 adjusted income ($18.4bn) due to non-recurring intangible impairments and losses on equity securities, accounting noise that does not reflect the operating business.
• The market extrapolates the patent-cliff headline without fully weighing that ex-COVID-19 growth already runs at +6% operational, funded by a diversified portfolio of twelve brands over $1 billion each.

This is not a case of an extreme discount: the base case projects a 5-year value barely in line with the current price, so the expected return leans more on the current dividend and execution of the savings programs than on aggressive multiple re-rating. The market is, with reason, pricing the real risk that the 2026-2030 patent cliff hits harder than modeled.

The annual return (CAGR at 5 years) in each scenario, with the total period return below — the margin of safety made visual: upside range wide, downside range narrow.

Even in the bear scenario, the return holds at -2%/year (-9% total): the margin of safety protects the downside. The bull (+12%/year, +75% total) exceeds it comfortably — a favorable asymmetry, with a narrow downside range and a wide upside range.

• Revenue concentration and 2026-2030 patent cliff. 12 products account for 65% of 2025 revenue; a significant revenue reduction is anticipated from exclusivity expirations, with the pace of decline expected to accelerate significantly.
• Pricing and reimbursement — MFN, IRA and TrumpRx. The voluntary agreement with the Trump Administration and the redesign of Medicare Part D under the IRA already cut 2025 revenue by ~$1,000 million, with the Maximum Fair Price reaching Eliquis, Ibrance, Xtandi and Xeljanz between 2026 and 2028.
• Regulatory and R&D approval risk. Drug discovery and development can take more than ten years and fail at any stage; the voluntary withdrawal of Oxbryta and the subsequent negative EMA opinion exemplify post-approval risk.
• Generic and biosimilar competition. Generic manufacturers typically operate without large R&D expenses and routinely challenge Pfizer's patents before expiration.
• Regulatory and legislative reform (OBBBA, EU pharmaceutical package, litigation). The OBBBA cuts Medicaid funding and could reduce demand; the EU pharmaceutical reform package takes effect in 2026; Pfizer actively litigates patent disputes whose outcome could bring forward generic entry.

Each thinker's analytical framework applied to our data.

• Buffett / Graham Quality + margin of safety

  Fails the quality gate: wide moat, eroding.

• Peter Lynch Growth at a reasonable price (GARP)

  A slow grower growing 3% at a multiple/growth of 7.2 → expensive for its growth.

• Joel Greenblatt Cheap and high-return (Magic Formula)

  Earnings yield 6% (EBIT/EV) + ROIC 9% → falls outside the Magic Formula.

• Howard Marks Perception vs reality + cycle

  The price discounts -10% vs our 3%: perception is more pessimistic than reality, with an identified source of the discount.

• Seth Klarman Capital protection (bear scenario)

  Bear-scenario floor -10%/yr over 5y (material loss) → risk of permanent capital loss.

• Pat Dorsey Moat strength (Five Rules)

  A wide moat, eroding; sources: intangibles, efficient scale, switching costs, cost advantage → partially passes the Five Rules.

• Aswath Damodaran Expectations implied by the price

  Justifying the price requires discounting -10%, within what we project (3%) — the story squares with the numbers.